Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

Pfizer slims down pipeline

September 28, 2010 Research and Development Pfizer

Pfizer has reduced the number of drugs in its product pipeline as part of a broad refocusing of its R&D …
News

European Commission eyes pharma ethics

September 27, 2010 Research and Development, Sales and Marketing European Commission, corporate responsibility, ethics

The European Commission is to examine corporate responsibility in the pharmaceutical industry with the aim of developing a series of …
News

Dr Alan Palmer joins One Nucleus

September 27, 2010 Research and Development One Nucleus, apppointment, research and development

Cambridge, UK-based life sciences body One Nucleus has appointed Dr Alan Palmer as a director. Alan is co-founder and chief …
Appointment

Gene-targeting asthma drugs within a decade

September 24, 2010 Research and Development asthma, genetic

Asthma treatments that target genetic variants found in people susceptible to the condition could be available within the next ten …
News

Solid results for AstraZeneca’s oral RA drug

September 23, 2010 Research and Development AstraZeneca, Rigel, fostamatinib, rheumatoid arthritis

AstraZeneca’s new oral treatment for rheumatoid arthritis has produced solid results in a phase II trial. Fostamatinib is the first …
News

Gilenya approved as new frontline MS treatment

September 22, 2010 Research and Development, Sales and Marketing Cladribine, FDA, Novartis, gilenya

Novartis’ new multiple sclerosis treatment Gilenya has been approved by the FDA, and is set to significantly alter the way …
News

Lixisenatide shaping up to rival Victoza

September 22, 2010 Research and Development Lixisenatide, Sanofi-Aventis, diabetes

Data for Sanofi-Aventis’ injectable lixisenatide suggests it could rival Novo Nordisk’s drug Victoza.Lixisenatide is a once-daily GLP-1 receptor agonist, and …
News

Public sceptical of pharma research

September 21, 2010 Research and Development Animal testing, Animal tests

Businesses including drug companies are seen as broadly untrustworthy or self-serving when it comes to medical research. This is one …
News

Medical, marketing & sales: making cross-functional working work

September 21, 2010 Research and Development, Sales and Marketing marketing, sales force effectiveness, sales representatives

A successful market access strategy requires the close collaboration of all functions within a pharmaceutical company. Most notably, the triumvirate …
Feature

Transition drops new diabetes drug

September 20, 2010 Research and Development Transition Therapeutics, diabetes, lilly

Transition Therapeutics is to abandon trials of its new diabetes treatment TT-223 following disappointing trial results. The Canadian biopharma company …
News

Novartis hails longer-lasting COPD drug

September 20, 2010 Research and Development, Sales and Marketing COPD, Novartis, Onbrez Breezhaler

A phase III treatment for COPD has demonstrated superior results over GSK’s established Serevent (salmeterol). Data from Novartis’ INSIST study …
News
GlaxoSmitKline logo

GSK workers in Ireland await review

September 20, 2010 Manufacturing and Production, Research and Development GlaxoSmithKline, Ireland, job cuts

Workers at a GlaxoSmithKline facility in Ireland are anxiously awaiting the outcome of an official review of the operation amid …
News
Alan_Watt

Cellzome hires GSK’s Alan Watt

September 20, 2010 Research and Development Cellzome, appointment, research and development

Cambridge, UK-based drug discovery and development company Cellzome has appointed Alan Watt to its senior management team as vice president …
Appointment

Contract research news in brief

September 20, 2010 Research and Development Covance, Galapagos, MediData Solutions, MediSync BioServices, PPD, Quotient Bioresearch, i3

A round-up of recent news from the CRO sector, featuring updates from Covance, Quotient Bioresearch, PPD, i3, Galapagos, MediSync BioServices …
News

GSK switches to subcutaneous route for antibody

September 16, 2010 Research and Development Arzerra, Genmab, GlaxoSmithKline, ofatumumab

GlaxoSmithKline says it will switch development of a new antibody treatment to a subcutaneous injection, to make it more commercially …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026